Zai Lab (NASDAQ:ZLAB) CEO Ying Du Sells 24,543 Shares of Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CEO Ying Du sold 24,543 shares of Zai Lab stock in a transaction on Friday, June 26th. The shares were sold at an average price of $17.46, for a total value of $428,520.78. Following the sale, the chief executive officer directly owned 1,192,840 shares of the company’s stock, valued at $20,826,986.40. This represents a 2.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ying Du also recently made the following trade(s):

• On Thursday, May 14th, Ying Du sold 50,000 shares of Zai Lab stock. The stock was sold at an average price of $20.09, for a total value of $1,004,500.00.
• On Monday, April 6th, Ying Du sold 2,653 shares of Zai Lab stock. The shares were sold at an average price of $20.45, for a total value of $54,253.85.
• On Thursday, April 2nd, Ying Du sold 5,576 shares of Zai Lab stock. The shares were sold at an average price of $20.39, for a total value of $113,694.64.

Zai Lab Trading Up 2.3%

Shares of NASDAQ ZLAB opened at $18.41 on Tuesday. Zai Lab Limited Unsponsored ADR has a 12 month low of $15.96 and a 12 month high of $41.20. The firm has a market capitalization of $2.09 billion, a price-to-earnings ratio of -11.36 and a beta of 0.79. The business has a 50-day moving average of $19.30 and a 200-day moving average of $18.95.

Zai Lab (NASDAQ:ZLAB) last announced its earnings results on Wednesday, April 1st. The company reported ($0.50) earnings per share for the quarter. Zai Lab had a negative net margin of 39.29% and a negative return on equity of 24.32%. The company had revenue of $99.61 million during the quarter. On average, analysts predict that Zai Lab Limited Unsponsored ADR will post -2.23 earnings per share for the current year.

Hedge Funds Weigh In On Zai Lab

An institutional investor recently raised its position in Zai Lab stock. SG Americas Securities LLC raised its holdings in shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 6.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 10,396 shares of the company’s stock after buying an additional 642 shares during the period. SG Americas Securities LLC’s holdings in Zai Lab were worth $183,000 at the end of the most recent reporting period. 41.65% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Wall Street Zen downgraded shares of Zai Lab from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. JPMorgan Chase & Co. lowered their price target on Zai Lab from $39.00 to $32.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 18th. Citigroup dropped their price target on Zai Lab from $47.00 to $44.00 and set a “buy” rating for the company in a research note on Friday, May 8th. Finally, Weiss Ratings upgraded Zai Lab from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.00.

Zai Lab Company Profile

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.